Proteomic Profiling of HL-60 Cells during ATRA-Induced Differentiation
- Authors: Vakhrushev I.V.1, Novikova S.E.1, Tsvetkova A.V.1, Karalkin P.A.1, Pyatnitskii M.A.1, Zgoda V.G.1, Yarygin K.N.1
- 
							Affiliations: 
							- V. N. Orekhovich Research Institute of Biomedical Chemistry
 
- Issue: Vol 165, No 4 (2018)
- Pages: 530-543
- Section: Сell Technologies in Biology and Medicine
- URL: https://journals.rcsi.science/0007-4888/article/view/240495
- DOI: https://doi.org/10.1007/s10517-018-4210-y
- ID: 240495
Cite item
Abstract
Acute promyelocytic leukemia, a form of acute myeloid leukemia, is characterized by cell differentiation arrest at the promyelocyte stage. Current therapeutic options include administration of all trans-retinoic acid (ATRA), but this treatment produces many side effects. ATRA is known to induce differentiation of leukemic cells into granulocytes, but the mechanism of this process is poorly studied. We performed comparative proteomic profiling of HL-60 promyelocytic cells at different stages of ATRA-induced differentiation to identify differentially expressed proteins by high-resolution mass spectrometry and relative quantitative analysis without isotope labels. A total of 1162 proteins identified by at least two unique peptides were analyzed, among them 46 and 172 differentially expressed proteins were identified in the nuclear and cytosol fractions, respectively. These differentially expressed proteins can represent candidate targets for combination therapy of acute promyelocytic leukemia.
About the authors
I. V. Vakhrushev
V. N. Orekhovich Research Institute of Biomedical Chemistry
							Author for correspondence.
							Email: vakhrunya@gmail.com
				                					                																			                												                	Russian Federation, 							Moscow						
S. E. Novikova
V. N. Orekhovich Research Institute of Biomedical Chemistry
														Email: vakhrunya@gmail.com
				                					                																			                												                	Russian Federation, 							Moscow						
A. V. Tsvetkova
V. N. Orekhovich Research Institute of Biomedical Chemistry
														Email: vakhrunya@gmail.com
				                					                																			                												                	Russian Federation, 							Moscow						
P. A. Karalkin
V. N. Orekhovich Research Institute of Biomedical Chemistry
														Email: vakhrunya@gmail.com
				                					                																			                												                	Russian Federation, 							Moscow						
M. A. Pyatnitskii
V. N. Orekhovich Research Institute of Biomedical Chemistry
														Email: vakhrunya@gmail.com
				                					                																			                												                	Russian Federation, 							Moscow						
V. G. Zgoda
V. N. Orekhovich Research Institute of Biomedical Chemistry
														Email: vakhrunya@gmail.com
				                					                																			                												                	Russian Federation, 							Moscow						
K. N. Yarygin
V. N. Orekhovich Research Institute of Biomedical Chemistry
														Email: vakhrunya@gmail.com
				                					                																			                												                	Russian Federation, 							Moscow						
Supplementary files
 
				
			 
					 
						 
						 
						 
						 
				 
  
  
  
  
  Email this article
			Email this article  Open Access
		                                Open Access Access granted
						Access granted Subscription Access
		                                		                                        Subscription Access
		                                					